However, for breast tumors with enhanced ABCG2 transporter activity, particularly TNBC where ABCG2 is often found expressed at a higher level than other types of breast tumors29, ALA-based modality needs to be combined with ABCG2 transporter inhibitors. The gene discussed is ABCG2; the disease is breast neoplasm.